Detection Technology (DETEC) Q3 2025 earnings summary

Executive summary

• Q3 2025 saw net sales decline by 8.8% year-over-year to €24.7 million, mainly due to unfavorable currency effects and reduced demand in security applications, with decreases across all regions and application areas.

• Nearly half of the sales decrease was attributed to currency fluctuations, with security applications and the Americas most affected.

• Profitability improved sequentially, but EBITA margin fell short of the prior year due to lower sales and product mix changes.

• Efficiency and reorganization measures were implemented globally, targeting cost savings of €0.4 million in H2 2025 and €1.5 million in FY 2026, with 13 job reductions and €0.3 million in non-recurring costs.

• Management expects a turning point, with double-digit net sales growth anticipated in Q1 2026.

Financial highlights

• Q3 2025 net sales were €24.7 million, down 8.8% year-over-year; EBITA excluding non-recurring items (NRI) was €2.8 million (11.4% margin); reported EBITA was €2.5 million (10.0% margin).

• For Q1–Q3 2025, net sales totaled €71.3 million, down 6.0% year-over-year; EBITA excluding NRI was €5.9 million (8.3% margin); reported EBITA was €5.6 million (7.8% margin).

• Cash flow from operating activities in Q3 was €0.5 million, and €2.4 million for Q1–Q3.

• Earnings per share for Q3 was €0.11 (vs. €0.22 last year), and €0.22 for Q1–Q3 (vs. €0.48 last year).

• Q3 investments were €0.5 million; for Q1–Q3, €2.1 million.

Outlook and guidance

• Q4 2025 net sales expected to decline year-over-year by a single digit, but double-digit sequential growth from Q3; Q1 2026 net sales expected to grow double digit.

• Industrial and medical segments expected to grow in Q4, while security and sales in EMEIA and Americas are expected to decline.

• Medium-term targets: annual sales growth of at least 10% and EBITA margin of 15%.

• Geopolitical risks, tariffs, and price competition in China remain key uncertainties.